Key Takeaways:
Spectral AI Inc. saw its stock fall after reporting a first-quarter net loss of $3.4 million, as declining revenue overshadowed the company’s progress toward securing regulatory clearance for its AI-powered DeepView burn assessment system.
"Our focus remains on advancing our DeepView technology and securing FDA clearance, which is crucial for our commercialization efforts," Vincent Capone, Chief Executive Officer of Spectral AI, said on the company's earnings call.
The medical device company reported revenue of $4.0 million for the quarter ended March 31, a drop from $6.7 million in the same period last year, which it attributed to the completion of a contract phase with the Biomedical Advanced Research and Development Authority (BARDA). The net loss compares to a net income of $2.9 million, or $0.11 per share, in the first quarter of 2025.
Despite the near-term financial dip, the company's value hinges on its De Novo application with the U.S. Food and Drug Administration, with a decision expected by the end of Q2 2026. A positive outcome would allow Spectral AI to begin commercializing the system by year-end, potentially unlocking a significant market in objective wound care assessment.
The company’s financial results reflect a period of transition. While revenue fell, gross margin improved to 50.8% from 47.2% a year earlier, which CFO David McGuire attributed to a higher concentration of direct labor. Cash reserves stood at $11.7 million as of March 31, down from $15.4 million at the end of 2025, reflecting a quarterly cash burn of $3.7 million as the company invests in research and commercialization initiatives.
The central focus for investors remains the DeepView system, which uses artificial intelligence to help clinicians predict the healing potential of burn wounds. Spectral AI submitted its application to the FDA in June 2025 and has been in active dialogue with the agency since. Capone stated the company hopes to move quickly to commercialize the device by the end of 2026 if clearance is granted. The company is working with Deloitte Consulting to finalize its strategy and plans an outcome study across 12 clinical sites to demonstrate the system's benefits.
Spectral AI is supported by a $31.7 million advanced funding award from BARDA, announced in March 2026, to accelerate development and procure up to 30 DeepView devices for trauma centers. However, Capone noted that most revenue from this funding will be recognized in 2027, not 2026. The company reiterated its full-year 2026 revenue guidance of approximately $18.5 million, which does not include any material contribution from DeepView system sales. The company also delivered a prototype of a handheld version of its device to the Medical Technology Enterprise Consortium (MTEC) ahead of schedule.
This article is for informational purposes only and does not constitute investment advice.
